Enzo Biochem, Inc. (NYSE:ENZ)’s stock price was up 8.3% on Friday . The stock traded as high as $4.01 and last traded at $3.93, approximately 169,876 shares traded hands during trading. A decline of 18% from the average daily volume of 208,015 shares. The stock had previously closed at $3.63.
Separately, TheStreet raised Howard Bancorp from a “c+” rating to a “b-” rating in a research report on Tuesday, July 2nd.
The company has a quick ratio of 5.12, a current ratio of 5.61 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average price of $3.61.
Enzo Biochem (NYSE:ENZ) last issued its earnings results on Monday, June 10th. The medical research company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Enzo Biochem had a negative return on equity of 34.02% and a net margin of 2.49%. The company had revenue of $19.66 million for the quarter.
In related news, major shareholder Discovery Fund Lp Harbert acquired 102,118 shares of the stock in a transaction dated Thursday, May 30th. The shares were acquired at an average price of $3.09 per share, with a total value of $315,544.62. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Harbert Management Corp acquired 63,677 shares of the stock in a transaction dated Tuesday, May 28th. The shares were bought at an average cost of $3.09 per share, for a total transaction of $196,761.93. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 179,927 shares of company stock worth $563,323. Insiders own 9.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Prudential Financial Inc. bought a new stake in Enzo Biochem during the 4th quarter valued at approximately $33,000. Strs Ohio boosted its stake in Enzo Biochem by 10.4% during the 1st quarter. Strs Ohio now owns 205,400 shares of the medical research company’s stock valued at $560,000 after purchasing an additional 19,300 shares during the period. Squarepoint Ops LLC boosted its stake in Enzo Biochem by 41.2% during the 4th quarter. Squarepoint Ops LLC now owns 203,402 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 59,346 shares during the period. Evermore Global Advisors LLC boosted its stake in Enzo Biochem by 1.3% during the 1st quarter. Evermore Global Advisors LLC now owns 4,586,419 shares of the medical research company’s stock valued at $12,521,000 after purchasing an additional 58,600 shares during the period. Finally, Sontag Advisory LLC bought a new stake in Enzo Biochem during the 4th quarter valued at approximately $43,000. 67.59% of the stock is currently owned by institutional investors and hedge funds.
About Enzo Biochem (NYSE:ENZ)
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
Recommended Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.